$HRMY
Harmony Biosciences Holdings Inc

2022 Q1 Form 10-Q Financial Statement

#000155837022006729 Filed on May 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $85.31M $59.67M
YoY Change 42.97% 200.78%
Cost Of Revenue $14.72M $10.41M
YoY Change 41.38% 199.97%
Gross Profit $70.60M $49.27M
YoY Change 43.3% 201.02%
Gross Profit Margin 82.75% 82.56%
Selling, General & Admin $35.46M $30.05M
YoY Change 18.0% 33.31%
% of Gross Profit 50.23% 61.0%
Research & Development $7.578M $4.679M
YoY Change 61.96% 36.37%
% of Gross Profit 10.73% 9.5%
Depreciation & Amortization $117.0K $100.0K
YoY Change 17.0% 3.09%
% of Gross Profit 0.17% 0.2%
Operating Expenses $43.04M $34.73M
YoY Change 23.92% 33.71%
Operating Profit $27.56M $14.53M
YoY Change 89.61% -251.24%
Interest Expense -$4.169M -$7.127M
YoY Change -41.5% 11.85%
% of Operating Profit -15.13% -49.04%
Other Income/Expense, Net -$2.000K -$20.00K
YoY Change -90.0%
Pretax Income $23.39M $7.386M
YoY Change 216.61% -119.12%
Income Tax $1.900M $0.00
% Of Pretax Income 8.12% 0.0%
Net Earnings $21.49M $7.386M
YoY Change 190.89% -119.12%
Net Earnings / Revenue 25.18% 12.38%
Basic Earnings Per Share $0.36 $0.13
Diluted Earnings Per Share $0.35 $0.13
COMMON SHARES
Basic Shares Outstanding 58.91M 56.89M
Diluted Shares Outstanding 60.59M 58.81M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $224.5M $141.2M
YoY Change 58.99%
Cash & Equivalents $224.5M $141.9M
Short-Term Investments
Other Short-Term Assets $3.410M $8.600M
YoY Change -60.35%
Inventory $4.597M $4.400M
Prepaid Expenses $9.618M
Receivables $38.13M $23.60M
Other Receivables $0.00 $0.00
Total Short-Term Assets $280.3M $177.7M
YoY Change 57.71%
LONG-TERM ASSETS
Property, Plant & Equipment $748.0K $800.0K
YoY Change -6.5%
Goodwill
YoY Change
Intangibles $178.8M
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.413M $900.0K
YoY Change 279.22%
Total Long-Term Assets $183.7M $159.6M
YoY Change 15.13%
TOTAL ASSETS
Total Short-Term Assets $280.3M $177.7M
Total Long-Term Assets $183.7M $159.6M
Total Assets $464.0M $337.3M
YoY Change 37.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.904M $4.400M
YoY Change 56.91%
Accrued Expenses $39.38M $28.80M
YoY Change 36.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M
YoY Change
Total Short-Term Liabilities $56.53M $33.40M
YoY Change 69.25%
LONG-TERM LIABILITIES
Long-Term Debt $189.9M $194.9M
YoY Change -2.57%
Other Long-Term Liabilities $3.078M $831.0K
YoY Change 270.4%
Total Long-Term Liabilities $193.0M $195.9M
YoY Change -1.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.53M $33.40M
Total Long-Term Liabilities $193.0M $195.9M
Total Liabilities $249.5M $229.4M
YoY Change 8.78%
SHAREHOLDERS EQUITY
Retained Earnings -$432.1M
YoY Change
Common Stock $646.6M $1.000K
YoY Change 64661500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $214.5M $107.9M
YoY Change
Total Liabilities & Shareholders Equity $464.0M $337.3M
YoY Change 37.56%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $21.49M $7.386M
YoY Change 190.89% -119.12%
Depreciation, Depletion And Amortization $117.0K $100.0K
YoY Change 17.0% 3.09%
Cash From Operating Activities $28.85M $12.53M
YoY Change 130.26% -146.93%
INVESTING ACTIVITIES
Capital Expenditures $45.00K $4.000K
YoY Change 1025.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$40.05M -$100.0M
YoY Change -59.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $500.0K
YoY Change
Cash From Financing Activities 1.383M 12.00K
YoY Change 11425.0% -99.98%
NET CHANGE
Cash From Operating Activities 28.85M 12.53M
Cash From Investing Activities -40.05M -100.0M
Cash From Financing Activities 1.383M 12.00K
Net Change In Cash -9.810M -87.46M
YoY Change -88.78% -285.85%
FREE CASH FLOW
Cash From Operating Activities $28.85M $12.53M
Capital Expenditures $45.00K $4.000K
Free Cash Flow $28.81M $12.53M
YoY Change 129.98% -146.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59030148
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58825769
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
CY2022Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001802665
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39450
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
CY2022Q1 dei City Area Code
CityAreaCode
484
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
539-9800
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
HRMY
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59048228
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224499000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38133000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34843000
CY2022Q1 us-gaap Inventory Net
InventoryNet
4597000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9618000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7637000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3410000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3218000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
280257000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
284439000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
748000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
820000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10409000
CY2022Q1 us-gaap Gross Profit
GrossProfit
70597000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
178837000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3413000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3515000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
183748000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
149004000
CY2022Q1 us-gaap Assets
Assets
464005000
CY2021Q4 us-gaap Assets
Assets
433443000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6904000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1001000
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4976000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9165000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39380000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3268000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1360000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
56528000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53775000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189896000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3078000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3177000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192974000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
193161000
CY2022Q1 us-gaap Liabilities
Liabilities
249502000
CY2021Q4 us-gaap Liabilities
Liabilities
246936000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59030148
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58825769
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
646615000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
640104000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-432113000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
214503000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
464005000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
433443000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85313000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59674000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14716000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7386000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58908526
CY2021Q1 us-gaap Gross Profit
GrossProfit
49265000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7578000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4679000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17583000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15506000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17880000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14547000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
43041000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
34732000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
27556000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
14533000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4169000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7127000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23385000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7386000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1900000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56891451
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60586875
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58805285
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1883000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4628000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
214503000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7386000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3301000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
107879000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
21485000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
7386000
CY2022Q1 us-gaap Depreciation
Depreciation
117000
CY2021Q1 us-gaap Depreciation
Depreciation
100000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5082000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4579000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4628000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3301000
CY2022Q1 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
268000
CY2021Q1 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-50000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
412000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
664000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
385000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
264000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3290000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1439000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
165000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
582000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2235000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
296000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
5903000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1835000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3586000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3200000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-152000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-32000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28852000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12530000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2022Q1 hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
CY2021Q1 hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40045000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100004000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
500000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1883000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1383000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9810000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-87462000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
225249000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141919000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
3829000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
6510000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-432113000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224499000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224499000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
225249000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of March 31, 2022, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 38% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 30% of gross accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 40% of gross accounts receivable; Pantherx, which accounted for 31% of gross accounts receivable; and CVS Caremark, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 38% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 30% of gross product revenues. For the three months ended March 31, 2021 three customers accounted for 100% of gross product revenues; Pantherx accounted for 38% of gross product revenues CVS Caremark accounted for 35% of gross product revenues; and Accredo accounted for 27% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for its product and active pharmaceutical ingredient.</p>
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
810000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
986000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
2362000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1787000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1874000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2108000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
5046000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
4881000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2022Q1 us-gaap Inventory Net
InventoryNet
4597000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5082000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4579000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
17884000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2022Q1 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
65573000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
178837000
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36163000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31081000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
178837000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2019Q3 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
2000000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
CY2019Q3 hrmy License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
102000000
CY2019Q3 hrmy Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
2000000
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13650000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13650000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2022Q1 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
19479000
CY2021Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
17141000
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
2120000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2125000
CY2022Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1256000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1983000
CY2022Q1 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
423000
CY2021Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
658000
CY2022Q1 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1554000
CY2021Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1645000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
898000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
301000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39380000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199500000
CY2022Q1 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
7104000
CY2021Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
7516000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
191896000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
191984000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189896000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1500000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
155500000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199000000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3824000
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6510000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
412000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
664000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4236000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
7174000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q4 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
13000
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
385000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
264000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.038
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3134000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1535000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1527000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2018000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2233000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3553000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3760000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
434000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
267000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
234000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1958000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1240000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1591000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
866000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3703000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
150000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3553000
CY2022Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0
CY2022Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5716597
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M2D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1377307
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
49.33
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
205432
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.35
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
63665
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
27.97
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6824807
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.29
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7260
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7270
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0237
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2021Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4896000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3251000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
95566000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7386000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58908526
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56891451
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60586875
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58805285
CY2022Q1 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1678349
CY2021Q1 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1913835
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5249666
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4871609
CY2022Q1 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0

Files In Submission

Name View Source Status
0001558370-22-006729-index-headers.html Edgar Link pending
0001558370-22-006729-index.html Edgar Link pending
0001558370-22-006729.txt Edgar Link pending
0001558370-22-006729-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrmy-20220331.xsd Edgar Link pending
hrmy-20220331x10q.htm Edgar Link pending
hrmy-20220331x10q_htm.xml Edgar Link completed
hrmy-20220331xex10d1.htm Edgar Link pending
hrmy-20220331xex31d1.htm Edgar Link pending
hrmy-20220331xex31d2.htm Edgar Link pending
hrmy-20220331xex32d1.htm Edgar Link pending
hrmy-20220331xex32d2.htm Edgar Link pending
hrmy-20220331_cal.xml Edgar Link unprocessable
hrmy-20220331_def.xml Edgar Link unprocessable
hrmy-20220331_lab.xml Edgar Link unprocessable
hrmy-20220331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending